About E3 ubiquitin-protein ligase RNF34
E3 ubiquitin-protein ligase RNF34 (RNF34) is a protein
from Homo sapiens identified by UniProt accession
Q969K3, 372 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNF34 |
|---|
| UniProt accession | Q969K3 |
|---|
| Gene | RNF34 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 372 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (65)
Diseases linked to this target (Open Targets).
- endometrial cancer · score 0.23
- squamous cell lung carcinoma · score 0.23
- gastric adenocarcinoma · score 0.23
- clear cell renal carcinoma · score 0.22
- urinary bladder cancer · score 0.19
- neutrophil percentage of leukocytes · score 0.19
- Agents acting on the renin-angiotensin system use measurement · score 0.18
- glucose measurement · score 0.17
- lymphocyte percentage of leukocytes · score 0.17
- lymphocyte count · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q969K3-F1 | alphafold | PREDICTED | 71.50 | — |
Amino-acid sequence (372 residues)
MKAGATSMWA SCCGLLNEVM GTGAVRGQQS AFAGATGPFR FTPNPEFSTY PPAATEGPNI VCKACGLSFS VFRKKHVCCD CKKDFCSVCS VLQENLRRCS TCHLLQETAF QRPQLMRLKV KDLRQYLILR NIPIDTCREK EDLVDLVLCH HGLGSEDDMD TSSLNSSRSQ TSSFFTRSFF SNYTAPSATM SSFQGELMDG DQTSRSGVPA QVQSEITSAN TEDDDDDDDE DDDDEEENAE DRNPGLSKER VRASLSDLSS LDDVEGMSVR QLKEILARNF VNYSGCCEKW ELVEKVNRLY KENEENQKSY GERLQLQDEE DDSLCRICMD AVIDCVLLEC GHMVTCTKCG KRMSECPICR QYVVRAVHVF KS
Explore E3 ubiquitin-protein ligase RNF34 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets